Search

Your search keyword '"Sogni, Philippe"' showing total 614 results
Start Over Author "Sogni, Philippe"
614 results on '"Sogni, Philippe"'

55. Reply to: “Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database”

Author

Depret, François, primary, Bouam, Samir, additional, Schwarzinger, Michaël, additional, Mallet, Vincent, additional, Depret, François, additional, Fontaine, Hélène, additional, Corouge, Marion, additional, Pichard, Anaïs Vallet, additional, Hollande, Clémence, additional, Sogni, Philippe, additional, and Pol, Stanislas, additional

Published
2022
Full Text
View/download PDF

56. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)

Author

BARRE, Tangui, MERCIE, Patrick, MARCELLIN, Fabienne, ESTERLE, Laure, DUVIVIER, Claudine, TEICHER, Elina, BUREAU, Morgane, CHAS, Julie, SALMON-CERON, Dominique, SOGNI, Philippe, CARRIERI, Maria Patrizia, WITTKOP, Linda, PROTOPOPESCU, Camelia, GROUP, Anrs Co Hepavih Study, Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], Hôpital Paul Brousse, DHU Hepatinov [Villejuif], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de Santé publique [CHU Bordeaux], CHU de bordeaux, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS CO13 HEPAVIH Study Group, Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Admin, Oskar, Centre Médical de l'Institut Pasteur, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]

Subjects
medicine.medical_specialty, Social Psychology, medicine.medical_treatment, media_common.quotation_subject, [SDV]Life Sciences [q-bio], HIV Infections, Hepacivirus, Smoking cessation, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Tobacco, Tobacco Smoking, Medicine, Humans, 030212 general & internal medicine, Chronic, ComputingMilieux_MISCELLANEOUS, media_common, Cannabis, biology, business.industry, Proportional hazards model, Coinfection, Human immunodeficiency virus, Hazard ratio, Public Health, Environmental and Occupational Health, virus diseases, Hepatitis C, Abstinence, medicine.disease, biology.organism_classification, 3. Good health, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cohort, 030211 gastroenterology & hepatology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Cohort study
Abstract

International audience; In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damages contribute greatly to morbidity and mortality in HIV-HCV co-infected patients. We used longitudinal data from the ANRS CO13 HEPAVIH cohort to identify the correlates of tobacco smoking quit attempts (TSQA) in HIV-HCV co-infected patients. TSQA were modelled using a multivariable discrete-time Cox proportional hazards model in 695 HIV-HCV co-infected tobacco smokers. HCV cure was associated with a 76% higher chance of TSQA (adjusted hazard ratio [95% confidence interval]: 1.76 [1.06-2.93], p = 0.029), and cannabis use with a 37% lower chance (0.63 [0.40-1.00], p = 0.049), independently of the mode of HIV transmission, other psychoactive substance use, and body mass index. Patients should be screened for tobacco and cannabis use at HCV treatment initiation and during follow-up. They should also be provided with comprehensive counselling and referral to addiction services. Non-smoking routes of cannabis administration should be promoted for cannabis users who wish to quit smoking tobacco.

Published
2021

58. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus

Author

Mallet, Vincent, primary, Parlati, Lucia, additional, Martinino, Alessandro, additional, Scarano Pereira, Juan Pablo, additional, Jimenez, Carmen Navas, additional, Sakka, Mehdi, additional, Bouam, Samir, additional, Retbi, Aurelia, additional, Krasteva, Donika, additional, Meritet, Jean-François, additional, Schwarzinger, Michaël, additional, Thabut, Dominique, additional, Rufat, Pierre, additional, Bonnefont-Rousselot, Dominique, additional, Sogni, Philippe, additional, Pol, Stanislas, additional, Tsochatzis, Emmanuel, additional, Fontaine, Hélène, additional, Corouge, Marion, additional, Pichard, Anaïs Vallet, additional, Hollande, Clémence, additional, Terris, Benoit, additional, Larger, Etienne, additional, Bertherat, Jérome, additional, Ratziu, Vlad, additional, and Hartemann, Agnès, additional

Published
2022
Full Text
View/download PDF

59. Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease

Author

De Broucker, Chloé, primary, Plessier, Aurélie, additional, Ollivier-Hourmand, Isabelle, additional, Dharancy, Sébastien, additional, Bureau, Christophe, additional, Cervoni, Jean-Paul, additional, Sogni, Philippe, additional, Goria, Odile, additional, Corcos, Olivier, additional, Sartoris, Riccardo, additional, Ronot, Maxime, additional, Vilgrain, Valérie, additional, de Raucourt, Emmanuelle, additional, Zekrini, Kamal, additional, Davy, Hortense, additional, Durand, François, additional, Payancé, Audrey, additional, Fidouh-Houhou, Nadira, additional, Yazdanpanah, Yazdan, additional, Valla, Dominique, additional, and Rautou, Pierre-Emmanuel, additional

Published
2022
Full Text
View/download PDF

62. An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).

Author

Bronowicki, Jean‐Pierre, Miailhes, Patrick, Hanslik, Bertrand, Ouzan, Denis, Larrey, Dominique, Riachi, Ghassan, Truchi, Régine, Jouannaud, Vincent, Pospait, Dan, Abergel, Armand, Causse, Xavier, Perot, Stéphanie, Skrzypski, Jérémy, De Hautecloque, Astrid, Spampinato, Axelle, Mariot, Philippe, and Sogni, Philippe

Subjects
CHRONIC hepatitis C, ALCOHOLISM, HEPATITIS C virus, TREATMENT effectiveness, FRENCH people
Abstract

Background and Aim: The efficacy and safety profiles of elbasvir–grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The present study was therefore designed to assess the real‐life effectiveness of EBR/GZR therapy in the general population and among subgroups with a high hepatitis C virus (HCV) prevalence in France. Methods: The Zephyr study was designed as a French, multicentre, prospective, observational study on EBR/GZR use and effectiveness in current practice in chronic hepatitis C patients. These results are based on data regarding the adult patients who received at least one dose of EBR/GZR between December 2017 and June 2019 in 67 French hospitals and clinics. Results: Overall, 478 patients were included. The Full Analysis Set corresponded to the 467 patients who met all the inclusion criteria and none of the exclusion criteria. Gender was balanced and the mean age was 55.7 ± 13.3 years. The patients were mainly treatment‐naive (89.5%) and infected with Genotype 1b (70.4%). Among the 75 patients with HCV Gt1a genotype, 56% had HCV RNA ≥ 800,000 IU/ml. F3–F4 fibrosis stage involved 24.2% of our population. Our subgroups were distributed among 110 migrants (23.6%), 58 (15.3%) using opioid agonist treatment, including people who inject drugs, 30 (6.8%) with chronic kidney disease Stages 3–5, 9 (1.9%) with an inherited blood disorder, and 4 (0.9%) coinfected with HIV. The remaining 269 (58.7%) were included in the general population subgroup. Overall, sustained virologic response 12 weeks after the end of treatment reached 98.0% and remained consistent among genotype, HCV RNA values, fibrosis stage, and the subgroup of interest. The rate of Alcohol Use Disorders Identification Test‐Consumption​​​ and Life Habit questionnaire completion was high at each visit, with data suggesting alcohol consumption decrease and an improvement in quality of life. Conclusions: Using real‐world evidence data on a French population representative of HCV patients, we confirmed the results obtained during EBR/GZR development program. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

63. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis

Author

Chalouni, Mathieu, Pol, Stanislas, Sogni, Philippe, Fontaine, Helene, Lacombe, Karine, Lacombe, Jean-Marc, Esterle, Laure, Dorival, Celine, Bourliere, Marc, Bani-Sadr, Firouze, De Ledinghen, Victor, Zucman, David, Larrey, Dominique, Salmon, Dominique, Carrat, Fabrice, Wittkop, Linda, ANRS CO13 HEPAVIH, Anrs C. O. Hepather Cohorts Study Groups, Martinez, V., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), INSERM-TRANSFERT [Paris] (IT), Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Joseph [Marseille], Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Bordeaux [Bordeaux], Hôpital Foch [Suresnes], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), MC was supported by a doctoral award from the French national Agency for Research on Aids and Viral Hepatitis (ANRS: France Recherche Nord & Sud Sida-HIV Hépatites), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris Cité (UPC)

Subjects
Sustained Virologic Response, medicine.medical_treatment, MESH: Sustained Virologic Response, HIV Infections, Hepacivirus, medicine.disease_cause, 0302 clinical medicine, Neoplasms, Pharmacology (medical), MESH: Hepacivirus, MESH: Neoplasms, 030212 general & internal medicine, Coinfection, Health Policy, Hazard ratio, virus diseases, Immunosuppression, MESH: HIV Infections, Hepatitis C, 3. Good health, MESH: Hepatitis C, Chronic, Infectious Diseases, Cohort, HCV, 030211 gastroenterology & hepatology, Non-liver-related cancers, MESH: Antiviral Agents, medicine.medical_specialty, Hepatitis C virus, MESH: Mediation Analysis, Antiviral Agents, 03 medical and health sciences, Internal medicine, medicine, Humans, Direct-acting antiviral (DAA) treatment, MESH: Hepatitis C, MESH: Humans, Mediation Analysis, business.industry, HIV coinfection, Cancer, Hepatitis C, Chronic, medicine.disease, Confidence interval, Indirect effect, MESH: Coinfection, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Metabolic syndrome, business
Abstract

International audience; OBJECTIVES: HIV-coinfected patients experience higher incidences of non-liver-related cancers than HCV-monoinfected patients. Chronic inflammation, immunosuppression, but also higher tobacco or alcohol consumption and metabolic dysregulation could explain this higher risk. We aimed to estimate the direct, indirect and total effects of HIV coinfection on the risk of non-liver-related cancers in HCV participants treated with direct-acting antivirals (DAAs). METHODS: Up to four HCV-monoinfected participants from the ANRS CO22 HEPATHER cohort were matched by age and sex to HIV/HCV-coinfected participants from the ANRS CO13 HEPAVIH cohort. Participants were followed from DAA initiation until the occurrence of a non-liver-related cancer. Counterfactual mediation analysis was carried out to estimate the direct (chronic inflammation and immunosuppression), indirect (tobacco and alcohol consumption and metabolic syndrome) and total effect of HIV coinfection on the risk of non-liver-related cancers. RESULTS: 548 HIV/HCV-coinfected and 2016 monoinfected participants were included. Overall, HIV coinfection was associated with a 3.7-fold [95% confidence interval (CI): 1.7-7.0] higher risk of non-liver-related cancers in HCV participants. This increased risk was explained by significant direct effect [hazard ratio (HR) = 3.4, 95% CI: 1.7-6.6] but not indirect effect (HR = 1.1, 95% CI: 0.8-1.5) of HIV coinfection. CONCLUSIONS: In HCV participants treated with DAAs, the direct effect of HIV coinfection, reflecting chronic inflammation and immunosuppression, was associated with a 3.7-fold higher risk of non-liver-related cancer. By contrast, the indirect effect of HIV coinfection, reflecting higher tobacco and alcohol consumption and metabolic dysregulation, was not significantly associated with the risk of non-liver-related cancers.

Published
2021

64. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020

Author

Mallet, Vincent, primary, Beeker, Nathanael, additional, Bouam, Samir, additional, Sogni, Philippe, additional, Pol, Stanislas, additional, Mallet, Vincent, additional, Beeker, Nathanaël, additional, Fontaine, Hélène, additional, Corouge, Marion, additional, Vallet Pichard, Anaïs, additional, Hollande, Clémence, additional, and Mehiri, Loriane Lair, additional

Published
2021
Full Text
View/download PDF

65. International French-speaking multicentre practice survey on hepatic hydrothorax (HH) : Results of the "Hep Hep" study among 529 hepatogastroenterologist (HG) or pneumologist (PN) respondents

Author

Cadranel, Jean-François, primary, Jacques, Cadranel, additional, Ollivier, Isabelle, additional, Thevenot, Thierry, additional, Nguyen-Khac, Eric, additional, Bureau, Christophe, additional, Allaire, Manon, additional, Nousbaum, Jean-Baptiste, additional, Loustaud-Ratti, Véronique, additional, Causse, Xavier, additional, Sogni, Philippe, additional, Hanslik, Bertrand, additional, Bourlière, Marc, additional, Péron, Jean-Marie, additional, Ganne-Carrié, Nathalie, additional, Dao, Thong, additional, Maitre, Bernard, additional, Elkrief, Laure, additional, Raherison, Chantal, additional, and Le Magoarou, Tristan, additional

Published
2021
Full Text
View/download PDF

71. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

Author

Barre, Tangui, Rojas Rojas, Teresa, Lacombe, Karine, Protopopescu, Camelia, Poizot-Martin, Isabelle, NISHIMWE, Marie, Zucman, David, Esterle, Laure, Billaud, Eric, Aumaitre, Hugues, Bouchaud, Olivier, Rey, David, Piroth, Lionel, Salmon-Ceron, Dominique, Wittkop, Linda, Sogni, Philippe, Carrieri, Maria Patrizia, Serfaty, Lawrence, Marcellin, Fabienne, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Subjects
Human immunodeficiency virus, Fatty liver, fungi, Metabolic diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Chronic, Hepatitis C, Cannabis
Abstract

Background: Cannabis use and elevated fatty liver index (FLI≥ 60) (a biomarker of hepatic steatosis in the general population) have been identified as predictors of HCV-related and overall mortality, respectively, in HIV-HCV co-infected patients. However, the relationship between cannabis use and the risk of elevated FLI has never been explored. Methods: Using five-year follow-up data from 997 HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort), we analyzed the relationship between cannabis use and FLI using mixed-effects multivariable logistic (outcome: elevated FLI yes/no) and linear (outcome: continuous FLI) regression models. Results: At the last follow-up visit, 27.4% of patients reported regular or daily cannabis use and 27.8% had elevated FLI. After multivariable adjustment, regular or daily cannabis use was associated with a 55% lower risk of elevated FLI (adjusted odds ratio [95% confidence interval]: 0.45 [0.22; 0.94]; p = 0.033) and lower FLI values (adjusted model coefficient: -4.24 [-6.57; -1.91], p

Published
2021

72. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort

Author

Pol, Stanislas, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Chevalier, Caroline, Hubert, Isabelle, Goepfert, Pierre, Lannes, Adrien, Lunel, François, Boursier, Jérôme, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Legendre, Amandine, Chermak, Faiza, Irlès-Depé, Marie, Ahmed, Si Nafa Si, Ansaldi, Christelle, Amara, Nisserine Ben, Oules, Valérie, Dunette, Jacqueline, Anty, Rodolphe, Gelsi, Eve, Truchi, Régin, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, Dieuleveult, Barbara De, Goin, Héloïse, Labarrière, Damien, Potier, Pascal, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverin, Monard, Rym, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F, Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphani, Ripault, Marie Pierre, Bureau, Christophe, Launay, Sarah, Peron, Jean Marie, Robic, Marie Angèl, Tarallo, Lé, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, E Montialoux, Hélè, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, E Angoulevant, Bénédic, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Vallée, Jean-Charles Duclos, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldin, Muti, Léo, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastie, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièl, Saillard, Eric, Lafrance, Marie-José, Nzinga, Clovis Luzivika, Dorival, Céline, Zoulim, Fabien, Cagnot, Carole, Decaens, Thomas, Thabut, Dominique, Asselah, Tarik, Mathurin, Philippe, Ganne, Nathalie, Samuel, Didier, Habersetzer, Françoi, Bronowicki, Jean-Pierre, Guyader, Dominique, Rosa, Isabelle, Leroy, Vincent, Chazouilleres, Olivier, Ledinghen, Victor De, Bourliere, Marc, Causse, Xavier, Cales, Paul, Metivier, Sophie, Loustaud-Ratti, Véroniqu, Abergel, Armand, Fontaine, Hélène, Carrat, Fabrice, Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
MESH: Antiviral Agents, MESH: Guanine, MESH: Hepatitis B virus, MESH: Humans, MESH: Tenofovir, MESH: Hepatitis B, Chronic, MESH: Liver Neoplasms, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Carcinoma, Hepatocellular, MESH: Prospective Studies, MESH: Treatment Outcome
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.Trial registration number: NCT019553458.

Published
2021

73. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

Author

Barré, Tangui, Pol, Stanislas, Ramier, Clémence, Di Beo, Vincent, Carrat, Fabrice, Bureau, Morgane, Bourlière, Marc, Dorival, Céline, Serfaty, Lawrence, Asselah, Tarik, Boursier, Jérôme, Marcellin, Fabienne, Carrieri, Patrizia, Fontaine, Hélène, Protopopescu, Camelia, Alric, Laurent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Zoulim, Fabien, Maynard, Marianne, Bai, Roxane, Hucault, Lucie, Bailly, François, Raffi, François, Billaud, Eric, Boutoille, David, Lefebvre, Maeva, André-Garnier, Elisabeth, Cales, Paul, Hubert, Isabelle, Lannes, Adrien, Lunel, Françoise, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Rousseaud, Emilie, Vallet-Pichard, Anaïs, Sogni, Philippe, Ledinghen, Victor De, Foucher, Juliette, Hiriart, Jean-Baptiste, M'Bouyou, Jancell, Irlès-Depé, Marie, Si Ahmed, Si Nafa, Oules, Valérie, Tran, Albert, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Thabut, Dominique, Hammeche, Saloua, Moussali, Joseph, Causse, Xavier, Dieuleveult, Barbara De, Ouarani, Brahim, Labarrière, Damien, Ganne, Nathalie, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverine, Ulker, Betul, Guyader, Dominique, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Habersetzer, François, Baumert, Thomas, Doffoel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Bronowicki, Jean-Pierre, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Larrey, Dominique, Meszaros, Magda, Metivier, Sophie, Bureau, Christophe, Morales, Thibault, Peron, Jean Marie, Robic, Marie Angèle, Decaens, Thomas, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Riachi, Ghassan, Goria, Odile, Paris, Fatima, Montialoux, Hélène, Leroy, Vincent, Amaddeo, Giuliana, Varaut, Anne, Simoes, Mélanie, Amzal, Rachida, Chazouillières, Olivier, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Samuel, Didier, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Abergel, Armand, Reymond, Maud, Brigitte, Chanteranne, Benjamin, Buchard, Muti, Léon, Geist, Claire, Conroy, Guillaume, Riffault, Raphaëlle, Rosa, Isabelle, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Loustaud-Ratti, Véronique, Carrier, Paul, Debette-Gratien, Maryline, Mathurin, Philippe, Lassailly, Guillaume, Lemaitre, Elise, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Minello, Anne, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, d'Alteroche, Louis, Barbereau, Didier, Nicolas, Charlotte, Elkrief, Laure, Jaillais, Anaïs, Gournay, Jérôme, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Portal, Isabelle, Gelu-Simeon, Moana, Saillard, Eric, Lafrance, Marie-Josée, Catherine, Lucie, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hôpital de Hautepierre [Strasbourg], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), and BOURGEAIS, Véronique

Subjects
Hepatitis B virus, medicine.medical_specialty, Cirrhosis, [SDV]Life Sciences [q-bio], Aucun, Overweight, medicine.disease_cause, Virus, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), Obesity, ComputingMilieux_MISCELLANEOUS, Cannabis, 030304 developmental biology, Pharmacology, 0303 health sciences, biology, Cannabinoids, business.industry, Liver Neoplasms, Hepatitis B, biology.organism_classification, medicine.disease, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Complementary and alternative medicine, Hepatocellular carcinoma, Cohort, cannabis, obesity, overweight, socioeconomic status, 030211 gastroenterology & hepatology, medicine.symptom, business
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection may evolve into cirrhosis and hepatocellular carcinoma, and this progression may be accelerated by specific risk factors, including overweight and obesity. Although evidence for a protective effect of cannabis use on elevated body weight has been found for other populations, no data are available for HBV-infected patients.Aims: We aimed to identify risk factors (including cannabis use) for overweight and obesity in patients with HBV chronic infection.Methods: Using baseline data from the French ANRS CO22 Hepather cohort, we performed two separate analyses, one using “central obesity” (based on waist circumference) and the other “overweight” and “obesity” (based on body mass index) as outcomes. Logistic and multinomial regressions were used to model central obesity and overweight/obesity, respectively.Results: Among the 3706 patients in the study population, 50.8% had central obesity, 34.7% overweight, and 14.4% obesity. After multivariable adjustment, current cannabis use was associated with a 59% lower risk of central obesity compared with no lifetime use (adjusted odds ratio [95% CI]: 0.41 [0.24 to 0.70]). It was also associated with a 54% and 84% lower risk of overweight (adjusted relative risk ratio [95% CI]: 0.46 [0.27 to 0.76]) and obesity (0.16 [0.04 to 0.67]), respectively.Conclusions: Cannabis use was associated with lower risks of overweight and obesity in patients with HBV chronic infection. Future studies should test whether these potential benefits of cannabis and cannabinoid use translate into reduced liver disease progression in this high-risk population.

Published
2021

79. Liste des collaborateurs

Author

ABDESSEMED, Amina, primary, AMOURA, Zahir, additional, AMIOUR, Farida, additional, ARTIFONI, Mathieu, additional, BADER-MEUNIER, Brigitte, additional, BALLONZOLI, Laurent, additional, BESSIS, Didier, additional, BORIE, Raphaël, additional, BRUCKERT, Éric, additional, COPPO, Paul, additional, COSTEDOAT-CHALUMEAU, Nathalie, additional, COUROUGE, Marion, additional, CRESTANI, Bruno, additional, DAÏEN-IMMEDIATO, Claire, additional, DE SEZE, Jérôme, additional, DIEUDÉ, Philippe, additional, DUPONT, Benoît, additional, DUZANSKI, Marie-Odile, additional, ESPITIA, Alexandra, additional, FRANCES, Camille, additional, GODEAU, Bertrand, additional, GOETZ, Joëlle, additional, GOMPEL, Anne, additional, GOTTENBERG, Jacques-Éric, additional, GUETTROT-IMBERT, Gaëlle, additional, HACHULLA, Éric, additional, HAYEM, Gilles, additional, HAMIDOU, Mohamed, additional, HULOT, Jean-Sébastien, additional, HUMBEL, René-Louis, additional, JAVIER, Rose-Marie, additional, LAZARO, Estibaliz, additional, LEFEBVRE, Maëva, additional, LE GUERN, Véronique, additional, LEROUX, Gaëlle, additional, LIPSKER, Dan, additional, MATHIAN, Alexis, additional, MATHIEU, Sylvain, additional, MARIETTE, Xavier, additional, MARRA, Donata, additional, MEYER, Olivier, additional, MOREL, Jacques, additional, MORELL-DUBOIS, Sandrine, additional, MOULIN, Bruno, additional, NÉEL, Antoine, additional, RICHEZ, Christophe, additional, PASQUALI, Jean-Louis, additional, PHILIPPI, Nathalie, additional, PIETTE, Jean-Charles, additional, PUECHAL, Xavier, additional, ROUX, Christian, additional, SALMON, Jean-Hugues, additional, SENET, Patricia, additional, SEROR, Raphaëlle, additional, SIBILIA, Jean, additional, SOGNI, Philippe, additional, SORDET, Christelle, additional, SOUBRIER, Martin, additional, SPRINGINSFELD, Géraldine, additional, REIMUND, Jean-Marie, additional, and VIENNOT, Stéphanie, additional

Published
2013
Full Text
View/download PDF

80. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

Author

Vallet-Pichard, Anais, primary, Correas, Jean-Michel, additional, Dorival, Celine, additional, Zoulim, Fabien, additional, Tran, Albert, additional, Bourlière, Marc, additional, Calès, Paul, additional, Guyader, Dominique, additional, Bronowicki, Jean-Pierre, additional, Larrey, Dominique, additional, Hezode, Christophe, additional, Loustaud-Ratti, Veronique, additional, Gournay, Jerome, additional, de Ledinghen, Victor, additional, Asselah, Tarik, additional, Ganne, Nathalie, additional, Metivier, Sophie, additional, Chazouillères, Olivier, additional, Leroy, Vincent, additional, Rosa, Isabelle, additional, Samuel, Didier, additional, Mathurin, Philippe, additional, Cagnot, Carole, additional, Fontaine, Helene, additional, Carrat, Fabrice, additional, Pol, Stanislas, additional, Bonnet, Delphine, additional, Payssan-Sicart, Virginie, additional, Pomes, Chloe, additional, Bailly, François, additional, Beaudoin, Marjolaine, additional, Giboz, Dominique, additional, Hartig-Lavie, Kerstin, additional, Maynard, Marianne, additional, Billaud, Eric, additional, Boutoille, David, additional, Cavellec, Morane, additional, Cheraud-Carpentier, Marjorie, additional, Hubert, Isabelle, additional, Benhida, Jaouad, additional, Lannes, Adrien, additional, Lunel, Françoise, additional, Oberti, Frédéric, additional, Boyer, Nathalie, additional, Giuily, Nathalie, additional, Castelnau, Corinne, additional, Scoazec, Giovanna, additional, Chibah, Aziza, additional, Keser, Sylvie, additional, Bonardi, Karim, additional, Vallet-Pichard, Anaïs, additional, Sogni, Philippe, additional, Foucher, Juliette, additional, Hiriart, Jean-Baptiste, additional, Wilson, Amy, additional, Shili, Sarah, additional, Chermak, Faiza, additional, Ansaldi, Christelle, additional, Amara, Nisserine Ben, additional, Chouquet, Laëtitia, additional, De Luca, Emilie, additional, Oules, Valérie, additional, Anty, Rodolphe, additional, Gelsi, Eve, additional, Truchi, Régine, additional, Luckina, Elena, additional, Messaoudi, Nadia, additional, Moussali, Joseph, additional, De Dieuleveult, Barbara, additional, Labarriere, Damien, additional, Poter, Pascal, additional, Ahmed, Si Nafa Si, additional, Grando-Lemaire, Véronique, additional, Nahon, Pierre, additional, Bourcier, Valérie, additional, Brulé, Séverine, additional, Stalhberger, Thomas, additional, Jezequel, Caroline, additional, Brener, Audrey, additional, Laligant, Anne, additional, Rabot, Aline, additional, Renard, Isabelle, additional, Baumert, Thomas F., additional, Dofföel, Michel, additional, Mutter, Catherine, additional, Simo-Noumbissie, Pauline, additional, Razi, Esma, additional, Barraud, Hélène, additional, Bensenane, Mouni, additional, Nani, Abdelbasset, additional, Hassani-Nani, Sarah, additional, Bernard, Marie-Albertine, additional, Pageaux, Georges-Philippe, additional, Bismuth, Michael, additional, Caillo, Ludovic, additional, Faure, Stéphanie, additional, Ripault, Marie-Pierre, additional, Bureau, Christophe, additional, Peron, Jean Marie, additional, Robic, Marie-Angèle, additional, Tarallo, Léa, additional, Faure, Marine, additional, Froissart, Bruno, additional, Hilleret, Marie-Noelle, additional, Zarski, Jean-Pierre, additional, Goria, Odile, additional, Grard, Victorien, additional, Montialoux, Hélène, additional, François, Muriel, additional, Ouedraogo, Christian, additional, Pauleau, Christelle, additional, Varault, Anne, additional, Andreani, Tony, additional, Angoulevant, Bénédicte, additional, Chevance, Azeline, additional, Serfaty, Lawrence, additional, Antonini, Teresa, additional, Coilly, Audrey, additional, Vallée, Jean-Charles Duclos, additional, Tateo, Mariagrazia, additional, Bonny, Corinne, additional, Brigitte, Chanteranne, additional, Lamblin, Géraldine, additional, Muti, Léon, additional, Babouri, Abdenour, additional, Filipe, Virginie, additional, Barrault, Camille, additional, Costes, Laurent, additional, Hagège, Hervé, additional, Merbah, Soraya, additional, Carrier, Paul, additional, Debette-Gratien, Maryline, additional, Jacques, Jérémie, additional, Lassailly, Guillaume, additional, Artu, Florent, additional, Canva, Valérie, additional, Dharancy, Sébastien, additional, Louvet, Alexandre, additional, Latournerie, Marianne, additional, Bardou, Marc, additional, Mouillot, Thomas, additional, Bacq, Yannick, additional, Barbereau, Didier, additional, Nicolas, Charlotte, additional, Chevalier, Caroline, additional, Archambeaud, Isabelle, additional, Habes, Sarah, additional, Botta-Fridlund, Danièle, additional, Saillard, Eric, additional, and Lafrance, Marie-Josée, additional

Published
2021
Full Text
View/download PDF

81. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

Author

Chalouni, Mathieu, primary, Pol, Stanislas, additional, Sogni, Philippe, additional, Fontaine, Hélène, additional, Lacombe, Karine, additional, Marc-Lacombe, Jean, additional, Esterle, Laure, additional, Dorival, Celine, additional, Bourlière, Marc, additional, Bani-Sadr, Firouzé, additional, de Ledinghen, Victor, additional, Zucman, David, additional, Larrey, Dominique, additional, Salmon, Dominique, additional, Carrat, Fabrice, additional, Wittkop, Linda, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaitre, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, and Lebrasseur-Longuet, D., additional

Published
2021
Full Text
View/download PDF

83. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and Hepatitis C virus: a CORIST-ANRS HC1 trial. (HIV/AIDS)

Author

Salmon-Ceron, Dominique, Lassalle, Regis, Pruvost, Alain, Benech, Henri, Bouvier-Alias, Magali, Payan, Christopher, Goujard, Cecile, Bonnet, Eric, Zoulim, Fabien, Morlat, Philippe, Sogni, Philippe, Perusat, Sophie, Treluyer, Jean-Marc, and Chene, Genevieve

Subjects
Ribavirin -- Dosage and administration, Ribavirin -- Evaluation, Interferon -- Dosage and administration, Interferon -- Evaluation, Stavudine -- Dosage and administration, Stavudine -- Evaluation, Hepatitis C -- Drug therapy, HIV infection -- Drug therapy, Health, Health care industry
Published
2003

90. Life after hepatitis C cure in HIV‐infected people who inject drugs and men who have sex with men treated with direct‐acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH)

Author

Mora, Marion, primary, Goodyear, Trevor, additional, Marcellin, Fabienne, additional, Shoveller, Jeannie, additional, Di Beo, Vincent, additional, Calzolaio, Chiara, additional, Sogni, Philippe, additional, Wittkop, Linda, additional, Zucman, David, additional, Poizot‐Martin, Isabelle, additional, Lacombe, Karine, additional, Salmon‐Céron, Dominique, additional, Knight, Rod, additional, and Carrieri, Patrizia, additional

Published
2020
Full Text
View/download PDF

92. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional

Published
2020
Full Text
View/download PDF

96. [FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients]

Author

Mallet, Vincent, Parlati, Lucia, Vallet-Pichard, Anaïs, Terris, Benoit, Tsochatzis, Emmanuel, Sogni, Philippe, Pol, Stanislas, Maternité Port-Royal [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lymphocytes et Immunité - Lymphocytes and Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Royal Free Hospital [London, UK], and University College of London [London] (UCL)

Subjects
Diagnosis, Differential, Liver Cirrhosis, Male, Liver Function Tests, Non-alcoholic Fatty Liver Disease, [SDV]Life Sciences [q-bio], Disease Progression, Health Status Indicators, Humans, Middle Aged, Biomarkers
Abstract

International audience; Key pointsThe FIB-4 index is a biomarker of advanced hepatic fibrosis in a context of fatty liver disease.The calculation of the FIB-4 index requires of age, serum ALT and AST transaminase levels and platelet count.A FIB-4 index < 1.45 in a context of fatty liver disease excludes clinically significant hepatic fibrosis.Additional explorations are mandatory to excluded hepatic fibrosis for a a FIB-4 index > 1.45 in a context of fatty liver disease.A complete hepatological workup is mandatory for a FIB-4 index > 3.25 in a context of fatty liver disease.; Points essentielsL’index FIB-4 est un biomarqueur simple pour diagnostiquer la fibrose hépatique avancée dans un contexte de stéatose.Le calcul de l’index FIB-4 nécessite de connaître l’âge, les transaminases ALT et AST et le taux de plaquettes.Un index FIB-4 < 1,45 dans un contexte de stéatose permet d’exclure une fibrose hépatique cliniquement significative.Un index FIB-4 > 1,45 dans un contexte de stéatose indique des explorations complémentaires, par exemple une élastométrie.Un index FIB-4 > 3,25 dans un contexte de stéatose évoque une fibrose hépatique avancée et indique une évaluation hépatologique complète.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results